Trending...
- Tampa-Based Digital Marketing Agency Launches New Website to Help Local Businesses Grow Online
- Global Families Turn to Young Travelers Concierge Amid Rising Safety Concerns in the U.S
- DuoKey to Unveil Encrypted Financial Intelligence Use Case at GISEC Global 2025
Neurolixis issued a new US patent for treatment of Fragile X syndrome with NLX-101
PARK RIDGE, N.J. - illiNews -- Neurolixis, Inc., a biopharmaceutical company that discovers and develops novel treatments to treat disorders of the brain, today announced that the United States Patent and Trademark Office (USPTO) granted a patent (US11974992B2) covering the use of NLX-101, a clinical phase drug candidate, for treatment of Fragile X syndrome (FXS). FXS is a rare genetic autism spectrum disorder which affects about 1 in 5000 individuals and is a leading cause of inherited intellectual disability. There are no approved treatments for Fragile X syndrome.
NLX-101 is a first-in-kind, selective serotonin 5-HT1A receptor 'biased agonist' which attenuates symptoms in a transgenic mouse model of FXS, suggesting that it can reduce anxiety and improve cognition in people with FXS. The patent, which is the fruit of a successful and ongoing collaboration between Neurolixis and researchers at the University of California, Riverside (UCR) and is being prosecuted by Neurolixis in other major pharmaceutical markets.
Professor Khaleel Abdulrazak, who supervised the experiments conducted by Dr. Xin Tao at UCR, commented: "People with Fragile X syndrome exhibit a range of debilitating symptoms, many of which can be modeled in transgenic mice. If the striking activity of NLX‑101 in the mice translates to the clinic, it could bring substantial benefits to patients and their carers."
More on illi News
"We are excited to expand the Neurolixis' rare disease program to Fragile X syndrome. We have already shown that NLX-101 has robust activity in transgenic models of Rett syndrome and the new patent expands our presence in the orphan autism disorder indication space. This is an important milestone as we embark on the development work required to initiate clinical studies in Fragile X syndrome patients," commented Adrian Newman-Tancredi, PhD, DSc, CEO of Neurolixis, Inc.
About NLX-101
NLX-101 acts on the brain's serotonin system and exhibits preferential activation of 5-HT1A receptors located in specific regions of the brain: such 'biased agonism' underlies its potent beneficial effects in animal models of cognition and mood. NLX-101 is an orally administered agent that has begun Phase 1 clinical in healthy volunteers. Neurolixis plans to investigate its ability to improve cognitive and mood dysfunction in Fragile X syndrome and other autism spectrum disorders.
About Fragile X Syndrome
Fragile X syndrome is a genetic disorder caused by a mutation in the FMR1 gene. It is the most common form of inherited intellectual disability and the leading cause of autism-like symptoms in males. Symptoms include intellectual disability, physical features, and behavioral symptoms. Genetic testing and physical examination are used for diagnosis. Supportive care and medications can help manage symptoms but there is no cure or approved treatment. The incidence of Fragile X syndrome is approximately 1 in 4,000 males and 1 in 8,000 females; in the United States 60 to 80 thousand individuals are affected.
More on illi News
About Neurolixis, Inc.
Neurolixis is a privately held biotechnology company developing therapies for disorders of the nervous system. The Company is focused on developing small molecule drugs for the treatment of disorders including Parkinson's disease, autism, depression and pain. Additional information regarding Neurolixis is available at http://www.neurolixis.com.
About the University of California, Riverside
UCR is a public research university located in Riverside, California, USA. It is one of the ten campuses of the University of California system. UCR is a research-intensive institution, with a strong focus on interdisciplinary research collaborations and innovation. The university has research expenditures of $200 million (2023) and is the only AAU and R1 institution in the Inland Empire of Southern California.
Forward Looking Statement
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including: our dependence on third parties for the development, regulatory approval and successful commercialization of our products, the inherent risk of failure in developing product candidates based on new technologies, risks associated with the costs of clinical development efforts, as well as other risks. Actual results may differ materially from those projected. These forward-looking statements represent our judgment as of the date of the release. Neurolixis disclaims any intent or obligation to update these forward-looking statements.
NLX-101 is a first-in-kind, selective serotonin 5-HT1A receptor 'biased agonist' which attenuates symptoms in a transgenic mouse model of FXS, suggesting that it can reduce anxiety and improve cognition in people with FXS. The patent, which is the fruit of a successful and ongoing collaboration between Neurolixis and researchers at the University of California, Riverside (UCR) and is being prosecuted by Neurolixis in other major pharmaceutical markets.
Professor Khaleel Abdulrazak, who supervised the experiments conducted by Dr. Xin Tao at UCR, commented: "People with Fragile X syndrome exhibit a range of debilitating symptoms, many of which can be modeled in transgenic mice. If the striking activity of NLX‑101 in the mice translates to the clinic, it could bring substantial benefits to patients and their carers."
More on illi News
- Mentor Agile Empowers Illinois Residents with Free Access To Product Management Training
- Midwest Pond Features & Landscapes Hits 100 Cleanouts This Spring, Expands Services Across Chicago
- Aureli Construction Sets the Standard for Seamless Home Additions in Greater Boston
- ScreenPoints Puts Film Investors in the Credits—and in the Money With New FinTech Platform
- Beyond Finance Wins Gold Stevie® Award for Customer Service Department of the Year in 23rd Annual American Business Awards
"We are excited to expand the Neurolixis' rare disease program to Fragile X syndrome. We have already shown that NLX-101 has robust activity in transgenic models of Rett syndrome and the new patent expands our presence in the orphan autism disorder indication space. This is an important milestone as we embark on the development work required to initiate clinical studies in Fragile X syndrome patients," commented Adrian Newman-Tancredi, PhD, DSc, CEO of Neurolixis, Inc.
About NLX-101
NLX-101 acts on the brain's serotonin system and exhibits preferential activation of 5-HT1A receptors located in specific regions of the brain: such 'biased agonism' underlies its potent beneficial effects in animal models of cognition and mood. NLX-101 is an orally administered agent that has begun Phase 1 clinical in healthy volunteers. Neurolixis plans to investigate its ability to improve cognitive and mood dysfunction in Fragile X syndrome and other autism spectrum disorders.
About Fragile X Syndrome
Fragile X syndrome is a genetic disorder caused by a mutation in the FMR1 gene. It is the most common form of inherited intellectual disability and the leading cause of autism-like symptoms in males. Symptoms include intellectual disability, physical features, and behavioral symptoms. Genetic testing and physical examination are used for diagnosis. Supportive care and medications can help manage symptoms but there is no cure or approved treatment. The incidence of Fragile X syndrome is approximately 1 in 4,000 males and 1 in 8,000 females; in the United States 60 to 80 thousand individuals are affected.
More on illi News
- Pathways to Adulthood Conference May 17 at Melville Marriott Honoring NYS Assembly Member Jodi Giglio, Suffolk County Legislator Nick Caracappa
- Adster Techologies awarded US Patent for breakthrough innovation in reducing latency in Ad Serving
- Mai Coffee Unveils First - Ever Vietnamese Coffee Pouches, Bringing "Viet Super Coffee" To The World
- Chris The Wiz Releases RAIN EP – A Cyberpunk Dreamscape in 4 Tracks
- Penetrium™ Breaks Oncology Barriers: The Solution to Cold Tumors and Metastatic Cancer Unveiled at AACR 2025
About Neurolixis, Inc.
Neurolixis is a privately held biotechnology company developing therapies for disorders of the nervous system. The Company is focused on developing small molecule drugs for the treatment of disorders including Parkinson's disease, autism, depression and pain. Additional information regarding Neurolixis is available at http://www.neurolixis.com.
About the University of California, Riverside
UCR is a public research university located in Riverside, California, USA. It is one of the ten campuses of the University of California system. UCR is a research-intensive institution, with a strong focus on interdisciplinary research collaborations and innovation. The university has research expenditures of $200 million (2023) and is the only AAU and R1 institution in the Inland Empire of Southern California.
Forward Looking Statement
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including: our dependence on third parties for the development, regulatory approval and successful commercialization of our products, the inherent risk of failure in developing product candidates based on new technologies, risks associated with the costs of clinical development efforts, as well as other risks. Actual results may differ materially from those projected. These forward-looking statements represent our judgment as of the date of the release. Neurolixis disclaims any intent or obligation to update these forward-looking statements.
Source: Neurolixis, Inc.
0 Comments
Latest on illi News
- The Tide Project Opens at Biennale Architettura 2025 in Venice Amplifying Youth Voices
- Wall Street analysts say BTC.XRP.DOGE cloud mining company SIX MINING is expected to achieve a 5-fold increase, allowing users to easily mine BTC
- Gen X Takes The Reins: New Book Guides Caregivers Juggling Parents, Kids, And Grandkids With Humor And Heart
- Naperville Welcomes Top Global Leaders Through Americas Competitiveness Exchange Visit
- Fray Fitness Launches Memorial Day Sale and Veteran Organization Giveaway
- ABM for Good™ Launches First Project with Build Change
- Local Nonprofit Files Lawsuit Against Trump Administration's Attack on AmeriCorps
- Pregis Honors Partners Driving Measurable Impact with Annual Pregis Purpose Awards
- ImagineX, in Collaboration with Qualys, Launches New mROC Services to Transform Enterprise Cyber Risk Management
- Ditch Micromanagement: New Leadership Book for Results-Driven, Accountability-Based Teams
- Jay Tapp was named Managing Director in British Columbia
- Hubei Heavy Equipment Makes a Striking Appearance at CIMT and Competes with International Brands
- 20 Patents Issued Worldwide, Cementing Company Leadership. First Ever Cable-Free 12-Lead ECG: HeartBeam, Inc. (Stock Symbol: BEAT)
- NASDAQ Uplisting for Higher Market Exposure and Wide Corporate Benefits to AI Boosted Marketing Company On Track Towards $1 Billion Revenue by 2027
- AAR announces investor conference schedule for May and June 2025
- Congressional Men's Health Caucus Shows Bipartisan Consensus and Focus on Prevention, Mental Health, and Closing the Lifespan Gap
- The Alternative AI Architecture That Creates Certainty and Trust - No More Guesses.
- DuoKey, Axiomtek and Blue Edge Network Partner to Enhance Smart Cities with Privacy-Preserving Urban Safeguarding and Fleet Management
- Naperville Police to Participate in Regional Route 59 Traffic Safety Initiative
- Women of Color Take the Stage at Fearless Summit to Scale, Heal, and Get Paid